Johnson & Johnson (JNJ) is a stock that I’ve moved around a bit on in the past few years. I’ve been pretty vehemently bearish at times, but more recently, I’ve been constructive on the stock as I felt the reaction to Q1 was overblown. The stock is up about 10 bucks since then, and while that’s not gangbusters by any means, it does position JNJ for its Q2 report – due out on Tuesday – to be of even greater importance. I’ll outline below my thoughts on how the stock is positioned going into the Q2 report as well as some things I’ll be watching surrounding the report.
Previewing Johnson & Johnson Earnings
7/17/17
By Josh Arnold, SeekingAlpha
Stories you Need to Know
- David Nevins Interviews Dr. Matthew Frieman, Associate Professor, University of Maryland School of Medicine
- Amneal Reports Fourth Quarter and Full Year 2020 Financial Results
- Insmed Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
- Provention Bio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
- Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial and Operational Results
- Pacira BioSciences Reports Full-Year and Fourth Quarter 2020 Financial Results
- MTBC Reports Record Full Year 2020 Results
- Aclaris Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update
- Merck to Acquire Pandion Therapeutics
- Madrigal Pharmaceuticals Reports 2020 Fourth Quarter and Full Year Financial Results and Highlights

